<table><tr><th>From:</th><th>Boris Nikolic</th></tr><tr><td>Sent:</td><td>Tuesday, August 27, 2013 6:34 PM</td></tr><tr><td>To:</td><td>Jeffrey Epstein (jeevacation@gmail.com)</td></tr><tr><td>Subject:</td><td>FW: Life Science companies / Gates</td></tr></table>

Below is an email (middle one) in which I requested that we included Founda=ion Medicine - which was not included in the list of company KPBC wanted t= present to Bill,

After I suggested that FM gets included KPBC agreed (email just below).

Even after that it took me several emails more as Foundation Medicine got o=itted. Will send you those.

Boris

-----Original Message-----
From: Risa Stack
Sent: Friday, September 7, 2012 6:54 AM
To: Boris Nikolic; Lila Ibrahim; Larry Cohen
Subject: Re: Life Science companies / Gates

Boris-

The CEO of Trius Jeff Stein would very much like to connect with you tadn i= optimistic that we can work together to resolve issues so we can move for=ard with a relationship.

Foundation Medicine is a great idea; the CEO Mike Pellini will be there! I =ill get you a full list of active life sciences companies in a few hours a=d more information on Foundation Medicine.

Looking forward to seeing you next week.

Risa

Risa Stack, Ph.D.
Partner
Kleiner Perkins Caufield & Byers
2750 Sand Hill Road
Menlo Park, CA 94025
Assistant
Barbara Bell

From: Boris Nikolic

>

Email details:
*   Date: Friday, September 7, 2012, 6:40 AM
*   To: Lila Ibrahim, Larry
*   Cc: Risa Stack
*   Subject: RE: Life Science companies / Gates

Thank you Lila!

How about Foundation Medicine?

Trius might be interesting as there are few issues that Foundation is tryin= to resolve.

Thank you

Boris

From: Lila Ibrahim [mailto Sent: Friday, September 07, 2012 6:37 AM To: Boris Nikolic; Larry Cohen Cc: Risa Stack Subject: Life Science companies / Gates

Larry & Boris,

I'm following-up on my conversation with Larry about potential life science=companies to meet next Friday.

We can meet with Trius for an update. You helped put them on a good path af=er our last meeting, but they've hit a few roadblocks. We think it's worth=a follow-up.

The other companies suggested - Calixa, Novadyne, Alphavax - are more matur= and/or we've exited. In other words, we aren't actively engaged in these =ompanies.

I've copied Risa Stack, one of our Life Science partners who you met in May=with Trius. She's pulling together a list of current companies to see if t=ere is 1-2 others you might be interested in. Boris -we previously passed =n meeting 3V BioSciences. We met with PacBio the day of their IPO in 2010.=We don't have many other therapeutic related investments.

Thanks for your guidance.

-lila

<?xml version=.0" encoding=TF-8"?>
<!DOCTYPE plist PUBLIC "-//Apple//DTD PLIST 1.0//EN" "http://www.apple.com/DTDs/PropertyList-1.0.dtd">
<plist version=.0">
<dict>
</dict>
</plist>

<key>conversation-id</key>
<integer>264597</integer>
<key>date-last-viewed</key>
<integer>0</integer>
<key>date-received</key>
<integer>1377628469</integer>

<key>flags</key>
<integer>8590195713</integer>
<key>gmail-label-ids</key>

<array>
<integer>6</integer>
<integer>2</integer>

</array>
<key>remote-id</key>
<string>336162</string>

</dict>

</plist>